By the same authors

From the same journal

Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine

Research output: Contribution to journalArticlepeer-review



Publication details

DateAccepted/In press - 12 Apr 2019
DateE-pub ahead of print - 22 May 2019
DatePublished (current) - 1 Jun 2019
Issue number6
Pages (from-to)595-611
Early online date22/05/19
Original languageEnglish


Mesenchymal stem cells (MSCs) are in development for many clinical indications, based both on “stem” properties (tissue repair or regeneration) and on signalling repertoire (immunomodulatory and anti-inflammatory effects). Potential conflation of MSC properties with those of tissue-derived stromal cells presents difficulties in comparing study outcomes and represents a source of confusion in cell therapy development. Cultured MSCs demonstrate significant heterogeneity in clonogenicity and multi-lineage differentiation potential. However in vivo biology of MSCs includes native functions unrelated to regenerative medicine applications, so do nomenclature and heterogeneity matter? In this perspective we examine some consequences of the nomenclature debate and heterogeneity of MSCs. Regulatory expectations are considered, emphasising that product development should prioritise detailed characterisation of therapeutic cell populations for specific indications.

Bibliographical note

© 2019 AJ Wilson, AJ Webster, PG Genever

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations